NQ 2040
Alternative Names: NQ-2040Latest Information Update: 20 Jul 2024
At a glance
- Originator Novaliq
- Class Eye disorder therapies; Neuroprotectants; Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy
Most Recent Events
- 11 Jul 2024 Preclinical trials in Diabetic retinopathy in Germany (Opthalmic) prior to July 2024 (Novaliq pipeline, July 2024)
- 11 Jul 2024 Novaliq targets a pre-IND meeting with the US FDA in 2025 for at least one API for a topical drug product for patients with non-proliferative Diabetic retinopathy therapy (Novaliq pipeline, July 2024)